Clinical Trial

BMB-101 in Absence Epilepsy and DEE

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 12, 2025 (before its estimated September 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
The study is a pilot, open-label, study to test whether BMB-101 is safe and effective in reducing the frequency of seizures in subjects with Absence Epilepsy including Epilepsy with Eyelid Myoclonia (also called Jeavons Syndrome) as well as Developmental Epileptic Encephalopathies such as Dravet and Lennox Gastaut. The study will last up to 6 months. There will be a 1 month screening period, then up to 3 months on open-label BMB-101 including titration and tapering/washout periods, and then a 1 month follow-up period. There will be 6 clinic visits.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-05-03; most recent amendment 2025-08-07.
Status change: Not Yet Recruiting → Recruiting 2024-12-12
Trial Details
NCT Number NCT06401538
Lead Sponsor Bright Minds Biosciences Pty Ltd
Conditions Absence Epilepsy, Jeavons Syndrome, Dravet Syndrome, Lennox Gastaut Syndrome
Enrollment 20 participants
Start Date 2024-12-05
Primary Completion 2025-09-15 (estimated)
Study Completion 2025-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-12